SOLICITATION NOTICE
66 -- Nucleofector II Device & Nucleofector Shuttle
- Notice Date
- 3/15/2009
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Field Finance & Acquisition Services, HFT-320, 3900 NCTR Road, Jefferson, Arkansas, 72079-9502
- ZIP Code
- 72079-9502
- Solicitation Number
- FDA-SOL-09-1055068
- Archive Date
- 4/14/2009
- Point of Contact
- Karen L Conroy,, Phone: 781-596-7715, Marcia O Park,, Phone: (870) 543-7405
- E-Mail Address
-
kconroy@ora.fda.gov, marcia.park@fda.hhs.gov
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 simplified acquisition procedures and the resultant pruchase order will include all applicable provision and clauses in effect through the Federal Acquistition Circular 2005-25, effective April 22. 2008. This announcement constitutes the only solicitation and a written solicitation will not be issued. The solicitation number is FDA-SOL-09-1055068. This synopsis, NAICS code is 541711 is to notify contractors that the government intends to issue a Purchase order in accordance with FAR Part 13.106 for the following statement of work, under the simplified acquisition procedures. This is a total small business set aside. Prospective offers are responsible for downloading the solicitation and any amendments. It is the offeror"s responsibility to monitor the Fed BizOPps website for the release of any amendments to this solicitation. The Government reserves the right to award a contract without discussion if the Contracting Officer determines that the initital offer(s) is are providing the Best Value and discussions are not necessary. This solicitation is issued as a Request for Quotes (RFQ). The Food and Drug Administration intends to award a purchase order for the equipment listed below. The transfection process is a manual process in most instances with very low efficiency. Some automated processes are offered, but are not designed for high throughput. The technology that we seek should be able to accommodate our studies in the providing the following: 1.The ability to transfer biologically active molecules (e.g.DNA, RNA, proteins of varying size) into the cytoplasm and into the nucleus of primary cells and cell lines without significant cell toxicity. 2.The ability to transfect non-dividing cells, such as neurons and resting blood cells. 3.High throughput transfection of single and multiple samples. 4.The instrument must have a single cuvette component, a 96-well format component, a laptop, including user friendly software interfaced with the system. 5.A 96 well independent format, with each well being pulsed and treated as an independent sample, thus giving the capacity to process 96 different conditions across the plate. 6.The capacity to transfer non-viral genes into primary cells and cell lines that are hard to transfect. 7.Transfected cells must be ready for analysis in 2-6hrs. 8.Machine must be able to provide very high efficiencies. Up to 95% transfection efficiency with DNA combined with viabilities greater than 95% and up to 99% siRNA duplex transfer in suspension cells. 9.Software interfaced with the system must be user friendly and provide protocols that are cell-type specific. 10.Reagents and components for use with the system must be cost efficient. Freight cost is to be added to prposal as a separate line item. Delivery to be made 30 days after award has been issued to the following location: Food & drug Administration -National Centerr for toxicologicval Research< Ofice of Associate Director for Regulatory Activities 3900 NCTR Road, Jefferson Arkansas 72079 Attn:Beverly Word An official authorized to bind the Offeror must sign the terms and conditions of the offer. Offerors that fail to finish required representations and certifications or reject the terms and condition of the soliciattion, may be excluded from consideration.. Contract type: Commercial Item-firm fixed price using Simplified Acquistion Procedures. The provision at FAR 212-1 Instruction to Offerors Commercial Items applie to this solicitation. The following addenda have been added to ths provision.The government will award a contract resulting from this solicitation to the responsible offeror whose offer is conforming to the solicitation will be The most advantageous to the Government. Price and other factoers considered. Award will be made to the lowest priced technically acceptable proposa. The government reserves the right to make an award without discusstion. Offers shall include technical specifications, descriptive material, lieteratur, brochures and other information corresponding to each minimum requirement, which demonstrates the capabilities of the offerors equipment. A standard commercial warenty on parts and workmanship is required. the Defense Priorities and Allications System and assigned rating are not applicable to this solicitation notice. CCR: Vendors must be registered in the Ecntral Contract rRegister (cCR) prior to the award of a contract. Yoy may register by going to www.ccr.gov. You will ned yoru Dun& Bradstreet number and banking information. Payment schedule:nety 30. All questions are to bwe submitted via e-mail to Karen.Conroy@fda.hhs.gov no later than March 26. 2009 no later than 2;00pm. QUOTATIONS ARE DUE MARCH 30, 2009 5;00PM EATERN STANDARD TIME VIA E-MAIL TO Karen.Conroy@fDA.HHS.Gov Provisions and Clauses: the following agenda have been attached. Offerors shall include a completed copy of the provision at FAR 52.212-3. Offer Represenations and Certifications Commercial Items. The clause at FAR 52.212-4, Contract Terms and Conditions, Commerical Items applies to this acquistion the clause at FAR 52.212-5 Contract Terms and conditions Required to Implement statues or Executive Order, Commercial Items applies to this acquisition. The followign fAER clauses are applicabel: FAR 52.217-8, FAR 52.222-26, FAR 52.222-35, fAR 52.222-36, and FAR 52.232-33. Clauses are provisions are incorporated by reference and apply to this acquistions. Responses to the notice must be sent via email to Kasren.Conroy@fda.hhs.gov. No phone calls will be accepted. All other solicitation requirements remain unchanged. amaxa, inc. is the sole company which develops and commercializes the Nucleofector™ Technology, and to date the Nucleofector™ Technology is not available from any distributor or dealer within the United States. The Nucleofector™ concept uses a unique combination of electrical parameters and cell-type specific Nucleofector™ solutions. Based on this combination, the Nucleofector™ Technology is the first efficient routine method for non-viral gene transfer into primary cells and hard-to-transfect cell lines. In addition, the Nucleofector™ Technology to date is unique in its ability to transfer DNA directly into the cell nucleus. The Nucleofector™ technology thus enables gene transfer into highly relevant cell types, often with unprecedented efficiencies.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=31fcc41f2ba9af8bb009f3c9ec22d32b&tab=core&_cview=1)
- Place of Performance
- Address: FDA-National Center for Toxicological Research, Office of Associate Director for Regulatory Activities, 3900 NCTRRoad, Attn: Beverly Word, Jefferson, Arkansas, 72079, United States
- Zip Code: 72079
- Zip Code: 72079
- Record
- SN01769585-W 20090317/090315213053-31fcc41f2ba9af8bb009f3c9ec22d32b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |